DC Combined With ICIs in the Treatment of Advanced Lung Cancer Resistant to ICIs

This study is testing a combination of dendritic cell (DC) therapy — a type of personalized immune treatment that trains the immune system to fight cancer — together with immunotherapy (immune checkpoint inhibitors) in people with advanced non-small cell lung cancer whose cancer has stopped responding to immunotherapy alone. Researchers hope this combination can "re-awaken" the immune system to attack the cancer again. **You may be eligible if:** - You are between 18 and 85 years old - You have been diagnosed with non-small cell lung cancer (NSCLC) at an advanced or metastatic stage - Your cancer progressed after receiving first-line chemotherapy combined with immunotherapy (PD-1/PD-L1 drugs) - Your blood counts, liver, and kidney function meet the required levels **You may NOT be eligible if:** - Your cancer has not received prior chemotherapy plus immunotherapy - Your blood counts, liver, or kidney results are outside acceptable ranges - You are pregnant or planning to become pregnant (without using effective contraception) Talk to your doctor to see if this trial is right for you.